Alpha Blue Ocean Group Announces the Launch of its Investment Banking Service Provider Division: ABO Transaction Advisory Services. Pierre Vannineuse Steps Down as CIO of ABO’s Investment Division to Lead ABO Transaction Advisory Services Full Time
21.2.2025 16:00:00 EET | Business Wire | Press release
ABO Group, a market leader in Europe for PIPE deals and complex public cross border M&As, announces the establishment of Alpha Blue Ocean Transaction Advisory Services LTD ("ABO-TAS"), a new division dedicated to offering Public Listing Advisory, Capital Raise Advisory, Non-Deal Roadshows, M&A, Management Consulting, Restructuring Advisory and other transaction advisory services.
ABO TAS is fully segregated and separate from the Alpha Blue Ocean Group’s Investment Division (which carries out the traditional investment activities of the ABO Group).
ABO Group’s investment banking services will leverage the decades of combined experience of the ABO TAS team in investment banking, Public ECM and DCM and most notably structured PIPEs and complex cross border transactions. On the consulting side, the ABO TAS team is dedicated to help businesses reach their maximum potential by capturing synergies between companies and its broad network of established relationships.
To spearhead this initiative, Pierre Vannineuse has been appointed as the Chief Executive Officer of ABO TAS. As part of this transition, he has stepped down from all roles within the Alpha Blue Ocean Group’s Investment Division, including his position as Chief Investment Officer, effective the end of 2024. Moving forward, Pierre Vannineuse will no longer be involved in the division’s daily operations, including trading and investment decisions, allowing him to fully concentrate on the expansion of ABO TAS.
ABO TAS’s Role and Mandate:
ABO TAS shall initially be engaged by the Alpha Blue Ocean Group’s Investment Division to source financing transactions. Under this mandate, ABO TAS will focus on the initial identification and execution of financing opportunities, while the Investment Division will retain full control over post-closing investment decisions (including, in particular, trading activities).
CEO Statement
“This marks an exciting new chapter for the Alpha Blue Ocean Group,” said Pierre Vannineuse, CEO of ABO TAS. “When I co-founded the group with Hugo Pingray, we envisioned transaction advisory services as a natural extension of our activities. ABO TAS will concentrate on investment banking services in M&A, reverse takeovers, restructuring, IPOs, and other advisory areas. However, we are actively exploring other lines of business, such as Lobbying, which would be a natural extension of our service profile. ABO TAS will focus on North America, Europe and Asia as part of its initial growth strategy”
Vannineuse emphasized the Alpha Blue Ocean Group’s innovative approach and first-mover advantage in its markets: “Leveraging our extensive experience, ABO TAS is poised to deliver exceptional value in this new arena. We are entering 2025 with several promising opportunities, setting the stage for a dynamic and productive year.”
Looking Ahead, Alpha Blue Ocean Group’s continued evolution reflects its commitment to innovation and adaptability in the financial sector. ABO TAS represents a strategic progression, leveraging the Group’s deep expertise to unlock new opportunities in transaction advisory services.
About ABO Group:
ABO Group is a diversified group of companies encompassing both buy side and sell side activities centered around public capital markets with the following fully segregated business units: ABO Asset Management (buy side), ABO Digital (Sell side), ABO Securities (buy side) and ABO Transaction Advisory Services (sell side).
ABO-TAS.com, ABODigital.IO and ABO.CO (IG)
About ABO TAS:
ABO TAS is the Investment Banking Service Provider Division of the ABO Group. This Sell Side entity of the group is dedicated to offering the following services to its public and private clients across North America and Europe: Public Listing Advisory, Capital Raise Advisory, Non-Deal Roadshows, M&A, Management Consulting, Restructuring Advisory and other transaction advisory services.
Press Contact ABO
pr@abo.co
View source version on businesswire.com: https://www.businesswire.com/news/home/20250221822685/en/
Contacts
Press Contact
Rajae Elantari
Alpha Blue Ocean Group
pr@abo.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom